Inhibitor Therapeutics, Inc.
Other OTCTotal Valuation
Inhibitor Therapeutics, Inc. carries a market capitalization of 14.50M, placing it among publicly traded companies globally. Its enterprise value stands at 17.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 14.50M |
| Enterprise Value | 17.53M |
Share Statistics
Inhibitor Therapeutics, Inc. currently has 172.57M shares outstanding.
| Shares Outstanding | 172.57M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.33 |
| P/TBV Ratio | -9.49 |
| P/FCF Ratio | -6.19 |
| P/OCF Ratio | -6.19 |
Financial Position
Inhibitor Therapeutics, Inc. maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.60 |
| Quick Ratio | 3.38 |
| Debt / Equity | -2.95 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -112.95 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Inhibitor Therapeutics, Inc.'s stock has gained approximately 68% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.07.
| Beta (5Y) | N/A |
| 52-Week Price Change | 68% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.07 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -3.45M, while operating income came in at -3.45M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -3.45M |
| Pretax Income | -3.35M |
| Net Income | -3.35M |
| EBITDA | -3.45M |
| EBIT | -3.45M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
Inhibitor Therapeutics, Inc. holds 1.29M in cash and equivalents against 58,361.00 in total debt, resulting in a net debt position of -1.29M. Total book value stands at -56.09M, with working capital of 993,633.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.29M |
| Total Debt | 58,361.00 |
| Net Debt | -1.29M |
| Equity (Book Value) | -56.09M |
| Book Value Per Share | -0.33 |
| Working Capital | 993,633.00 |
Cash Flow
Inhibitor Therapeutics, Inc. produced -3.03M in operating cash flow over the past twelve months.
| Operating Cash Flow | -3.03M |
| Capital Expenditures | N/A |
| Free Cash Flow | -3.03M |
| FCF Per Share | -0.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -16.15 |
Scores
Inhibitor Therapeutics, Inc. posts an Altman Z-Score of -58.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -58.61 |